## FDA Fast-Tracks Three Psychedelic Treatments for Depression and PTSD in Rare Policy Shift
The Food and Drug Administration is accelerating its review of three psychedelic-based treatments for mental health disorders, marking a notable shift in the agency's approach to these controversial yet increasingly studied substances. The agency granted priority review vouchers to Compass Pathways, the Usona Institute, and Transcend Therapeutics for their respective candidates targeting treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder.

Compass Pathways received a voucher for its psilocybin product aimed at treatment-resistant depression, while Usona's similar psilocybin formulation targets major depressive disorder. Transcend Therapeutics secured acceleration for its MDMA-like experimental treatment for PTSD. The FDA confirmed the medications selected but did not officially name the companies—Compass independently confirmed its inclusion, with the remaining firms identified by a person familiar with the matter. Priority review vouchers typically shorten the regulatory timeline from standard review periods, a significant advantage in a field where development cycles have stretched over decades.

The move aligns with broader signals from the Trump administration to expand access to alternative mental health treatments amid growing recognition of limitations in existing therapies. Psychedelic-assisted treatments have faced persistent regulatory skepticism due to safety concerns and their classification as Schedule I substances under federal law. However, clinical data suggesting therapeutic potential in severe cases has steadily accumulated, creating pressure on regulators to respond. Industry observers note this marks one of the most visible federal receptions to psychedelic medicine to date, though the path to full approval and widespread clinical use—if it comes—would still require substantial evidence and infrastructure for supervised administration protocols.
---
- **Source**: STAT News
- **Sector**: The Lab
- **Tags**: FDA, psychedelics, psilocybin, MDMA, mental health
- **Credibility**: unverified
- **Published**: 2026-04-24 19:54:06
- **ID**: 76946
- **URL**: https://whisperx.ai/en/intel/76946